Related Experiment Video

Updated: Nov 24, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

C Louwrens Braal1, Elisabeth M Jongbloed2, Saskia M Wilting2

  • 1Department of Medical Oncology, Erasmus University MC Cancer Institute, Dr. Molewaterplein 40, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. c.braal@erasmusmc.nl.

Drugs
|December 28, 2020
PubMed

Insights

Cyclin-dependent kinase (CDK) 4/6 inhibitors are new breast cancer drugs. This review compares palbociclib, ribociclib, and abemaciclib, aiding optimal patient treatment selection.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cyclin-dependent kinase (CDK) 4/6 inhibitors represent a novel therapeutic class targeting cell cycle progression in cancer.
  • Palbociclib, ribociclib, and abemaciclib are approved CDK4/6 inhibitors for breast cancer treatment.
  • These agents are crucial in managing hormone receptor-positive, HER2-negative (HR+, HER2-) breast cancer.

Purpose of the Study:

  • To review the clinical pharmacokinetic and pharmacodynamic profiles of three CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib.
  • To highlight similarities and differences among these agents to guide individualized treatment choices.
  • To discuss future directions for the clinical application of CDK4/6 inhibitors in breast cancer therapy.

Main Methods:

  • Review of clinical pharmacokinetic data for palbociclib, ribociclib, and abemaciclib.
  • Review of clinical pharmacodynamic data for the three CDK4/6 inhibitors.
  • Analysis of comparative efficacy and safety profiles in various treatment settings.

Main Results:

  • All three CDK4/6 inhibitors demonstrate significant efficacy in HR+, HER2- breast cancer.
  • While pharmacokinetically and pharmacodynamically similar, subtle differences exist between palbociclib, ribociclib, and abemaciclib.
  • These differences may influence the selection of a specific agent for individual patient management.

Conclusions:

  • CDK4/6 inhibitors are integral to the treatment of HR+, HER2- breast cancer.
  • Understanding the nuanced pharmacokinetic and pharmacodynamic profiles is essential for optimizing therapeutic selection.
  • Further research is needed to fully establish the optimal clinical applicability of these agents.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.6K
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs10:38

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

2.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K